SynthesisPloS one2017
Follicle Stimulating Hormone is an accurate predictor of azoospermia in childhood cancer survivors.
Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- ESHRE good practice recommendations on fertility preservation involving testicular tissue cryopreservation in children receiving gonadotoxic therapies†.Human reproduction (Oxford, England) · 2025Guideline
- The impact of vincristine on testicular development and function in childhood cancer.Human reproduction update · 2023Pooled it
- Impacts of platinum-based chemotherapy on subsequent testicular function and fertility in boys with cancer.Human reproduction update · 2020Pooled it
- Trial
- Semen analysis and reproductive hormones in boys with classical Hodgkin lymphoma treated according to the EuroNet-PHL-C2 protocol.Human reproduction (Oxford, England) · 2024Trial
- Trial
- Long-term outcome and chimerism in patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation: a retrospective nationwide survey.International journal of hematology · 2019Trial
- Pubertal Testicular Function in Childhood Cancer Survivors and Future Fertility.JAMA network open · 2026Article
- Endocrine late-effects in survivors of childhood and adolescence cancer: clinical management.Journal of endocrinological investigation · 2026Review
- Long-term endocrine and testicular outcomes in male survivors of childhood acute lymphoblastic leukemia.Journal of endocrinological investigation · 2026Article
- Male infertility as a late side effect of oncological treatment of Hodgkin lymphoma in childhood and adolescents and the possible prevention.Frontiers in oncology · 2025Review
- Fertility Potential and Gonadal Function in Survivors of Reduced-Intensity Hematopoietic Stem Cell Transplantation.Transplantation and cellular therapy · 2024Article
- Is ongoing testosterone required after pubertal induction in Duchenne muscular dystrophy?Endocrine connections · 2023Article
- Reproductive ability in survivors of childhood, adolescent, and young adult Hodgkin lymphoma: a review.Human reproduction update · 2023Review
- Interest in fertility status assessment among young adult survivors of childhood cancer.Cancer medicine · 2023Article
- Fertility preservation and monitoring in adult patients diagnosed with lymphoma: consensus-based practical recommendations by the Fondazione Italiana Linfomi & Società Italiana della Riproduzione Umana.Frontiers in oncology · 2023Article
- Fertility-related worry among emerging adult cancer survivors.Journal of assisted reproduction and genetics · 2022Article
- Azoospermic men with isolated elevation of folliclestimulating hormone represent a specific subpopulation of patients with poor reproductive outcomes.Clinical and experimental reproductive medicine · 2022Article
- A Novel Locus Predicts Spermatogenic Recovery among Childhood Cancer Survivors Exposed to Alkylating Agents.Cancer research · 2020Article
- Fertility preservation in boys: recent developments and new insightsHuman reproduction open · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
The accuracy of Follicle Stimulating Hormone as a predictor of azoospermia in adult survivors of childhood cancer is unclear, with conflicting results in the published literature. A systematic review and post hoc analysis of combined data (n = 367) were performed on all published studies containing extractable data on both serum Follicle Stimulating Hormone concentration and semen concentration in survivors of childhood cancer. PubMed and Medline databases were searched up to March 2017 by two blind investigators. Articles were included if they contained both serum FSH concentration and semen concentration, used World Health Organisation certified methods for semen analysis, and the study participants were all childhood cancer survivors. There was no evidence for either publication bias or heterogeneity for the five studies. For the combined data (n = 367) the optimal Follicle Stimulating Hormone threshold was 10.4 IU/L with specificity 81% (95% CI 76%-86%) and sensitivity 83% (95% CI 76%-89%). The AUC was 0.89 (95%CI 0.86-0.93). A range of threshold FSH values for the diagnosis of azoospermia with their associated sensitivities and specificities were calculated. This study provides strong supporting evidence for the use of serum Follicle Stimulating Hormone as a surrogate biomarker for azoospermia in adult males who have been treated for childhood cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.